Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and